Misonidazole is a radiosensitizer that was investigated in clinical trials. It was used in these trials for radiation therapy to cause normally resistant hypoxic tumor cells to become sensitive to the treatment.[1][2]

Misonidazole
Names
IUPAC name
(RS)-1-Methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.033.559 Edit this at Wikidata
EC Number
  • 236-931-6
KEGG
MeSH D008920
UNII
  • InChI=1S/C7H11N3O4/c1-14-5-6(11)4-9-3-2-8-7(9)10(12)13/h2-3,6,11H,4-5H2,1H3 ☒N
    Key: OBBCSXFCDPPXOL-UHFFFAOYSA-N ☒N
  • InChI=1/C7H11N3O4/c1-14-5-6(11)4-9-3-2-8-7(9)10(12)13/h2-3,6,11H,4-5H2,1H3
    Key: OBBCSXFCDPPXOL-UHFFFAOYAQ
  • COCC(CN1C=CN=C1[N+](=O)[O-])O
Properties
C7H11N3O4
Molar mass 201.182 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

See also

edit

References

edit
  1. ^ Meißner, Rebecca; Feketeová, Linda; Illenberger, Eugen; Denifl, Stephan (2019). "Reactions in the Radiosensitizer Misonidazole Induced by Low-Energy (0–10 eV) Electrons". International Journal of Molecular Sciences. 20 (14): 3496. doi:10.3390/ijms20143496. PMC 6678818. PMID 31315268.
  2. ^ Overgaard, Jens (2011). "Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A systematic review and meta-analysis". Radiotherapy and Oncology. 100 (1): 22–32. doi:10.1016/j.radonc.2011.03.004. PMID 21511351.